BR112023019904A2 - Anticorpos específicos para il-38 - Google Patents

Anticorpos específicos para il-38

Info

Publication number
BR112023019904A2
BR112023019904A2 BR112023019904A BR112023019904A BR112023019904A2 BR 112023019904 A2 BR112023019904 A2 BR 112023019904A2 BR 112023019904 A BR112023019904 A BR 112023019904A BR 112023019904 A BR112023019904 A BR 112023019904A BR 112023019904 A2 BR112023019904 A2 BR 112023019904A2
Authority
BR
Brazil
Prior art keywords
antibodies
metastasis
antigen
specific antibodies
tumor growth
Prior art date
Application number
BR112023019904A
Other languages
English (en)
Inventor
Ben Harman
Fang Shen
Karen Lundgren
K Robinson Matthew
A Nikitin Pavel
Original Assignee
Immunome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunome Inc filed Critical Immunome Inc
Publication of BR112023019904A2 publication Critical patent/BR112023019904A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

anticorpos específicos para il-38. a presente invenção refere-se a anticorpos específicos para interleucina-38 (il-38) humana, incluindo anticorpos isolados, ou fragmentos de ligação a antígeno dos mesmos. os anticorpos, ou fragmentos de ligação a antígeno dos mesmos, descritos neste pedido bloqueiam parcial ou completamente, inibem, ou neutralizam uma atividade biológica da il 38. os métodos descritos neste pedido referem-se à inibição do crescimento tumoral ou metástase em um indivíduo acometido de crescimento tumoral e/ou metástase.
BR112023019904A 2021-03-28 2022-03-28 Anticorpos específicos para il-38 BR112023019904A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163167105P 2021-03-28 2021-03-28
US202163236454P 2021-08-24 2021-08-24
PCT/US2022/071382 WO2022213050A1 (en) 2021-03-28 2022-03-28 Il-38-specific antibodies

Publications (1)

Publication Number Publication Date
BR112023019904A2 true BR112023019904A2 (pt) 2023-12-05

Family

ID=83459938

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023019904A BR112023019904A2 (pt) 2021-03-28 2022-03-28 Anticorpos específicos para il-38

Country Status (10)

Country Link
US (1) US20240174741A1 (pt)
EP (1) EP4313131A1 (pt)
JP (1) JP2024511906A (pt)
KR (1) KR20240004375A (pt)
AU (1) AU2022246948A1 (pt)
BR (1) BR112023019904A2 (pt)
CA (1) CA3215306A1 (pt)
IL (1) IL307175A (pt)
TW (1) TW202302635A (pt)
WO (1) WO2022213050A1 (pt)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008251943B2 (en) * 2007-03-14 2013-09-05 Alexion Pharmaceuticals, Inc. Humaneered anti-factor B antibody
CA3049189A1 (en) * 2017-01-10 2018-07-19 Yamaguchi University Anti-gpc3 antibody
AU2020323591A1 (en) * 2019-07-30 2022-03-17 Immunome, Inc. IL-38 specific antibodies

Also Published As

Publication number Publication date
AU2022246948A1 (en) 2023-10-05
AU2022246948A9 (en) 2024-02-22
KR20240004375A (ko) 2024-01-11
JP2024511906A (ja) 2024-03-15
EP4313131A1 (en) 2024-02-07
US20240174741A1 (en) 2024-05-30
TW202302635A (zh) 2023-01-16
CA3215306A1 (en) 2022-10-06
WO2022213050A1 (en) 2022-10-06
IL307175A (en) 2023-11-01

Similar Documents

Publication Publication Date Title
MX2021007156A (es) Inhibidores de kif18a.
BR112019010595A2 (pt) anticorpo ou fragmento de ligação ao antígeno do mesmo, combinação de moléculas de ácido nucleico isoladas, composição farmacêutica, kit, e, método para selecionar um composto.
BR112021017430A2 (pt) Inibidores da proteína tirosina fosfatase e métodos de uso dos mesmos
PH12020552116A1 (en) Bispecific anti-psma x anti-cd28 antibodies and uses thereof
EA202092825A1 (ru) Анти-sirpa антитела и способы их применения
CO2021009004A2 (es) Anticuerpos biespecíficos anti-cd28 x anti-cd22 y usos de estos
MX2022001181A (es) Inhibidores de kif18a.
PH12021551238A1 (en) Bispecific Anti-MUC16 x Anti-CD28 Antibodies and Uses Thereof
BR112017005110A2 (pt) anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo, molécula isolada de ácido nucleico, composição farmacêutica, e, método para diminuir níveis de glicose no sangue ou para tratar uma condição ou doença.
CO2021000447A2 (es) Inhibidores de proteína tirosina fosfatasa y sus métodos de uso
BR112022003956A2 (pt) Anticorpos anti-cd73
BR112022015416A2 (pt) Anticorpos anti-ror1 e composições
BR112021014074A2 (pt) Proteínas de ligação ao antígeno anti-receptor il2 gama
BR112022007284A2 (pt) Inibição de integrina humana alpha-4 beta-7
BR112016030730A8 (pt) composto
MX2022005866A (es) Anticuerpos biparatopicos frente a cd73.
BR112015021483A2 (pt) arginina deiminase com reduzida reatividade cruzada para anticorpos adi-peg 20 para o tratamento do câncer
BR112022004972A2 (pt) Anticorpos, ácidos nucleicos isolados, células hospedeiras isoladas, métodos de produção de um anticorpo, de produção de um anticorpo biespecífico e de tratamento de um indivíduo, anticorpos biespecíficos, composição farmacêutica, anticorpo, anticorpo biespecífico ou composição farmacêutica, combinação de um anticorpo, uso do anticorpo, uso de uma combinação do anticorpo e métodos para reduzir a inflamação e para melhorar a descamação e/ou de erupção cutânea e combinação para uso
BR112021019854A2 (pt) Anticorpos anti-sema3a e seus usos para o tratamento dos olhos ou de doenças oculares
BR112021025077A2 (pt) Anticorpos anti-sortilina para uso em terapia
BR112017023158A2 (pt) anticorpos anti-ap2 e agentes de ligação de antígeno para tratar distúrbios metabólicos
BR112022024262A2 (pt) Métodos de tratamento de nefropatia por iga com um anticorpo de ligação a april
CL2022000294A1 (es) Composiciones biofarmacéuticas y procedimientos conexos.
BR112021019524A2 (pt) Uso de anticorpo anti-pd-1 na preparação de medicamento para tratamento de tumores sólidos
BR112023019904A2 (pt) Anticorpos específicos para il-38